Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, JULY 06, 2026 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A TRANSFORMATIVE PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES BROADLY TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASE, TODAY ANNOUNCED THAT PRELIMINARY CLINICAL DATA FROM THE COMPANY'S OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE, FT819, WILL BE PRESENTED AT THE INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH (ISSCR) 2026 ANNUAL MEETING, BEING HELD AT THE PALAIS DES CONGRS DE MONTRAL IN MONTRAL, CANADA ON JULY 8 - 11, 2026.

FATE THERAPEUTICS TO PRESENT PRELIMINARY CLINICAL DATA OF FT819 OFF-THE-SHELF CAR T-CELL PRODUCT CANDIDATE FOR SYSTEMIC SCLEROSIS AT THE ISSCR 2026 ANNUAL MEETING

SAN DIEGO, JULY 01, 2026 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A TRANSFORMATIVE PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN THE THIRD QUARTER OF 2026.

FATE THERAPEUTICS TO PARTICIPATE IN UPCOMING THIRD QUARTER 2026 CONFERENCES

ACCOMPLISHED GLOBAL COMMERCIAL OPERATIONS LEADER BRINGS DEEP EXPERIENCE LAUNCHING AND SCALING BIOPHARMACEUTICAL PRODUCTS AS FATE ADVANCES ITS PIPELINE TOWARD COMMERCIALIZATION ACCOMPLISHED GLOBAL COMMERCIAL OPERATIONS LEADER BRINGS DEEP EXPERIENCE LAUNCHING AND SCALING BIOPHARMACEUTICAL PRODUCTS AS FATE ADVANCES ITS PIPELINE TOWARD COMMERCIALIZATION

FATE THERAPEUTICS APPOINTS LAURA HAMILL TO BOARD OF DIRECTORS

FT819 OFF-THE-SHELF CAR T-CELL THERAPY PRODUCT CANDIDATE CONTINUES TO BROADEN PATIENT ACCESS WITH 21 SLE PATIENTS NOW TREATED, INCLUDING AS OUTPATIENT ADMINISTRATION IN COMMUNITY HOSPITALS CONTINUED DEMONSTRATION OF RAPID AND SUSTAINED CLINICAL IMPROVEMENT WITH FAVORABLE TOLERABILITY PROFILE OBSERVED FOLLOWING TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS WITH FT819 AND LESS-INTENSIVE CONDITIONING CHEMOTHERAPY; A MAJORITY OF EVALUABLE PATIENTS ON BACKGROUND GLUCOCORTICOIDS ACHIEVED EITHER COMPLETE GLUCOCORTICOID DISCONTINUATION OR GUIDELINE-BASED TAPERING TARGETS FT819 DEMONSTRATED DEEP B-CELL DEPLETION WITH RECONSTITUTION OF PREFERRED LESS-DIFFERENTIATED STATE ASSOCIATED WITH A HEALTHIER REPERTOIRE OF B CELLS; ELIMINATION OF DOMINANT B-CELL CLONES IN DOSE-DEPENDENT MANNER WAS SEEN WHILE VACCINATION TITERS WERE MAINTAINED IN PRECLINICAL STUDIES, FT839 EXHIBITED COMPREHENSIVE ELIMINATION OF ACTIVATED IMMUNE CELLS IN RHEUMATOID ARTHRITIS PATIENT SAMPLES; ACTIVITY ACCOMPLISHED WHILE IN ALLOGENEIC SETTING WITHOUT THE NEED FOR CONDITIONING CHEMOTHERAPY SAN DIEGO, JUNE 04, 2026 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A TRANSFORMATIVE PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES BROADLY TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASE, PRESENTED DATA TODAY FEATURING ITS OFF-THE-SHELF CAR T-CELL PROGRAMS FT819 AND FT839 AT THE EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR) ANNUAL MEETING BEING HELD IN LONDON, UK, JUNE 3-6, 2026. THE DATA PRESENTED FOR FT819 WITH LESS-INTENSIVE CONDITIONING AND OFF-THE-SHELF CAR T-CELL THERAPY PRODUCT CANDIDATE IN SLE IS TRULY EXCITING, AND WE ARE VERY PLEASED THAT OUR HIGHLY-DIFFERENTIATED THERAPEUTIC APPROACH HAS THE POTENTIAL TO TRANSFORM AUTOIMMUNE DISEASE OUTCOMES BY SUPPORTING PERSISTENT REDUCTIONS IN CSLEDAI, PGA, FACIT-FATIGUE, AND UPCR SCORES AND PROMOTING EFFECTIVE B-CELL DEPLETION WITH PREFERRED SUBTYPE REC

FATE THERAPEUTICS SHOWCASES DATA FROM FT819 AND FT839 PROGRAMS AT THE EUROPEAN CONGRESS OF RHEUMATOLOGY ANNUAL MEETING

SAN DIEGO, JUNE 02, 2026 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A TRANSFORMATIVE PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES BROADLY TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ON JUNE 1, 2026, THE COMPANY GRANTED RESTRICTED STOCK UNITS (RSUS) REPRESENTING 67,300 SHARES OF ITS COMMON STOCK TO TWO NEWLY-HIRED NON-EXECUTIVE EMPLOYEES. THE GRANTS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S AMENDED AND RESTATED INDUCEMENT EQUITY PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4). THE RSUS WILL VEST OVER FOUR YEARS, WITH 25% OF THE SHARES UNDERLYING EACH RSU AWARD VESTING ON EACH ANNIVERSARY OF THE GRANT DATE, SUBJECT TO THE EMPLOYEES BEING CONTINUOUSLY EMPLOYED BY THE COMPANY THROUGH EACH VESTING DATE.

FATE THERAPEUTICS REPORTS NEW EMPLOYEE INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

FT836 DEMONSTRATES MEANINGFUL REDUCTION IN TARGET LESIONS WITHOUT THE USE OF CONDITIONING CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER DETECTION OF FT836 IN THE PERIPHERAL BLOOD AND TUMOR TISSUE ILLUSTRATES THE UNIQUE ABILITY TO TRAFFIC TO TUMOR SITE AND FUNCTIONALLY PERSIST WITHOUT THE RELIANCE ON CONDITIONING CHEMOTHERAPY IN ALLOGENEIC PATIENT SETTING SAN DIEGO, JUNE 01, 2026 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A TRANSFORMATIVE PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES BROADLY TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASES, PRESENTED CLINICAL DATA THIS WEEKEND FEATURING ITS OFF-THE-SHELF CAR T-CELL PROGRAM FT836 AT THE AMERICAN SOCIETY OF CANCER ONCOLOGY (ASCO) ANNUAL MEETING BEING HELD IN CHICAGO, IL, MAY 29  JUNE 2, 2026. "EARLY PHASE 1 DATA FOR FT836 REPRESENTS A TRULY EXCITING MOMENT FOR PATIENTS WITH CERTAIN ADVANCED SOLID TUMORS WHO HAVE EXHAUSTED THEIR TREATMENT OPTIONS SAID BOB VALAMEHR, PH.D.

FATE THERAPEUTICS SHOWCASES CLINICAL DATA FOR FT836 AT THE AMERICAN SOCIETY OF CANCER ONCOLOGY ANNUAL MEETING

SAN DIEGO, MAY 21, 2026 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A TRANSFORMATIVE PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT DATA FROM ITS OFF-THE-SHELF CAR T-CELL PROGRAMS WILL BE FEATURED AT THE AMERICAN SOCIETY OF CANCER ONCOLOGY ANNUAL MEETING TO BE HELD IN CHICAGO, IL, MAY 29  JUNE 2, 2026 AND AT THE EUROPEAN CONGRESS OF RHEUMATOLOGY BEING HELD IN LONDON, UK, JUNE 3-6, 2026.

FATE THERAPEUTICS ANNOUNCES PRESENTATIONS AT 2026 ASCO AND EULAR ANNUAL MEETINGS HIGHLIGHTING OFF-THE-SHELF CAR T-CELL THERAPY PIPELINE FOR CANCER AND AUTOIMMUNE DISEASES

RECLAIM  LN, A PHASE 2 POTENTIALLY REGISTRATIONAL CLINICAL TRIAL OF FT819 IN PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WITH LUPUS NEPHRITIS, ON SCHEDULE TO INITIATE IN THE 2 ND HALF OF 2026

FATE THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATES

SINGLE DOSE TREATMENT OF FT819 WITHOUT CONDITIONING CHEMOTHERAPY ACHIEVES LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) IN ACTIVE SLE PATIENTS; DURABLE B CELL REMODELING IS EXHIBITED BY DEPLETION OF MAJOR B CELL CLONES UP TO 12 MONTHS FOLLOWING TREATMENT WITH B CELL SHIFT TOWARDS LESS CLASS-SWITCHED BCR REPERTOIRE

FATE THERAPEUTICS SHOWCASES FT819 CLINICAL ACTIVITY IN SLE WITHOUT THE USE OF CONDITIONING CHEMOTHERAPY AT THE 2026 ASGCT ANNUAL MEETING

FDA CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) DEVELOPMENT AND READINESS PILOT (CDRP) PROGRAM SUPPORTS THE ACCELERATION OF MANUFACTURING READINESS FOR THERAPIES WITH EXPEDITED CLINICAL DEVELOPMENT TIMELINES CURRENT REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION AND CDRP PARTICIPATION PROVIDE OPPORTUNITY FOR EXPEDITED REGULATORY PATHWAY AND ADVANCEMENT OF FT819 PHASE 2 POTENTIALLY REGISTRATIONAL CLINICAL TRIAL IN PATIENTS WITH REFRACTORY MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WITH LUPUS NEPHRITIS SAN DIEGO, MAY 05, 2026 (GLOBE NEWSWIRE) -- FATE THERAPEUTICS, INC. (NASDAQ: FATE), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO BRINGING A TRANSFORMATIVE PIPELINE OF INDUCED PLURIPOTENT STEM CELL (IPSC)-DERIVED CELLULAR IMMUNOTHERAPIES BROADLY TO PATIENTS WITH CANCER AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS SELECTED FT819 FOR PARTICIPATION IN THE CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) DEVELOPMENT AND READINESS PILOT (CDRP) PROGRAM FOR TREATMENT OF MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). THE FDA CDRP PROGRAM IS A HIGHLY SELECTIVE INITIATIVE, WITH NO MORE THAN NINE PROPOSALS ACCEPTED ANNUALLY ACROSS THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) AND THE CENTER FOR DRUG EVALUATION AND RESEARCH (CDER).

FATE THERAPEUTICS SELECTED FOR U.S. FDA CHEMISTRY, MANUFACTURING, AND CONTROLS DEVELOPMENT AND READINESS PILOT PROGRAM TO SUPPORT MANUFACTURING READINESS OF FT819

Fate Therapeutics, Inc.

FATE

Price

Financial Reports

No items found.

Press Releases

Fate Therapeutics, Inc.

FATE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

FATE